Tag: pharmaceuticals
-
Peanut Desensitizing Found Safe, Effective Long-Term
A clinical trial shows children with peanut allergies taking peanut protein under the tongue avoid allergic reactions from peanuts for up to five years.
-
Gates Investing in HIV, Tuberculosis Immunotherapies
The Bill and Melinda Gates Foundation is taking an equity stake in a biotechnology company developing immunotherapies from messenger RNA.
-
Deep Learning Techniques Speed Drug Discovery
Researchers developed and demonstrated techniques with deep learning to discover new small molecule drugs ready for validation and lab animal tests in 21 days.
-
Companies Call for Genome Editing Regulations
A group of companies developing treatments for disease using genome editing are calling for regulations and standards to govern these technologies in regenerative medicine.
-
Patch Designed for Vaccines, Cancer Treatments
An engineering team designed a small skin patch with tiny needles that in lab mice quickly delivers vaccines and possibly treatments for melanoma.
-
Crispr Deployed for Programmable Smart Hydrogels
Bio-engineers developed a process using the gene editing technique Crispr to design gel materials with properties added for drug delivery, diagnostics, and electronic circuits.
-
Small Biz Grant Funds Pre-Term Gut Microbe Therapy
National Institutes of Health is supporting development of an extended-release probiotic treatment for necrotizing enterocolitis, an intestinal disease affecting premature infants.
-
Carb-X Funds Drug-Resistant Bacterial Vaccine
A company developing vaccines with synthetic biology is receiving a grant for a vaccine to prevent infections from drug-resistant Klebsiella pneumoniae bacteria.
-
FDA Okays Celiac Disease Engineered Microbe Trial
A company making synthetic biological therapies received authorization to begin clinical trials in the U.S. for an engineered microbe to treat celiac disease.
-
Aging Therapy Network Adds $100M to Venture Round
An enterprise supporting a group of companies developing new drugs to address the aging process raised another $100 million in its second venture funding round.